DOR Biopharma Inc.
Formerly ENDOREX CORP, IMMUNOTHERAPEUTICS INC
DOR Biopharma Inc. is listed today as Soligenix, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2017 | $2 M | Private placement after listing | Under $2 million | equity | SEC | |
| Apr 2013 | $2 M | Private placement after listing | Under $2 million | equity | SEC | |
| Jun 2010 | $6 M | No. 4 | $2 to $10 million | equity, options | SEC | |
| Feb 2009 | $5 M | No. 3 | $2 to $10 million | equity | SEC | |
| Jan 2009 | $2 M | No. 2 | $2 to $10 million | equity, options | SEC | |
| Dec 2008 | $2 M | No. 1 | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Soligenix, Inc., its revenue in fiscal 2024 came from these product and service lines: Grant revenue $120,000 (100%).
Annual report (SEC XBRL) · Dec 2024
DOR Biopharma Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2017).
SEC Form D · Nov 2017
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2017
Products and services#
No products or services of DOR Biopharma Inc. are on record.
Investors#
No investor of DOR Biopharma Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 46 investors.
Largest shareholders today
Institutions holding Soligenix, Inc. shares, as of Sep 30, 2026.
- Citadel Advisors LLC$0 M2.69%
- XTX Topco Ltd$0 M0.63%
- Geode Capital Management, LLC$0 M0.45%
- Vanguard Capital Management LLC$0 M0.35%
- Jane Street Group, LLC$0 M0.27%
- StoneX Group Inc.$0 M0.24%
- Vanguard Fiduciary Trust Co$0 M0.23%
- Renaissance Technologies LLC$0 M0.19%
- Northern Trust Corp$0 M0.16%
- Virtu Financial LLC$0 M0.08%
- Two Sigma Securities, LLC$0 M0.06%
- Citigroup Inc$0 M0.04%
- Morgan Stanley$0 M0.02%
- UBS Group AG$0 M0.01%
- Wells Fargo & Company/mn$0 M0.01%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Adam T. Rumage | Executive officer | Nov 2017 |
| Christopher J. Schaber, PhD | Executive officer | Nov 2017 |
| Karen Christopher Krumeich | Executive officer | Nov 2017 |
| Oreola Christopher Donini, PhD | Executive officer | Nov 2017 |
| R. Christopher Cavalli, PhD | Executive officer | Nov 2017 |
| Richard C. Straube, MD MSc | Executive officer | Nov 2017 |
| Christopher J. Schaber, Ph.D. | Executive officer | May 2013 |
| Joseph M. Warusz, C.P.A. | Executive officer | May 2013 |
| Kevin J. Horgan, M.D. | Executive officer | May 2013 |
| Robert N. Brey, Ph.D. | Executive officer | May 2013 |
| Brian L. Hamilton, M.D., Ph.D. | Executive officer | Jul 2010 |
| Christopher P. Schnittker, C.P.A. | Executive officer | Jul 2010 |
| Evan J. Myrianthopoulos | Executive officer | Jul 2010 |
| Christopher J Schaber | Executive officer | Feb 2009 |
| Evan Myrainthopoulos | Executive officer | Feb 2009 |
| James Clavijo | Executive officer | Feb 2009 |
| Evan Myrianthopoulos | Executive officer | Feb 2009 |
| Robert N Brey | Executive officer | Feb 2009 |
| Christopher J. Schaber, PhD | Director | Nov 2017 |
| Gregg A. LaPointe, CPA | Director | Nov 2017 |
| Jerome B. Zeldis, PhD | Director | Nov 2017 |
| Keith L. Brownlie, CPA | Director | Nov 2017 |
| Marco M. Brughera, DVM | Director | Nov 2017 |
| Robert J. Rubin, MD | Director | Nov 2017 |
| Christopher J. Schaber, Ph.D. | Director | May 2013 |
| Gregg A. Lapointe, C.P.A. | Director | May 2013 |
| Jerome B. Zeldis, M.D., Ph.D. | Director | May 2013 |
| Keith L. Brownlie, C.P.A. | Director | May 2013 |
| Robert J. Rubin, M.D. | Director | May 2013 |
| Cyrille F. Buhrman | Director | Jul 2010 |
| Evan J. Myrianthopoulos | Director | Jul 2010 |
| Gregg A. Lapointe, C.P.A., M.B.A. | Director | Jul 2010 |
| Christopher J Schaber | Director | Feb 2009 |
| Cyrille F Buhrman | Director | Feb 2009 |
| Evan Myrainthopoulos | Director | Feb 2009 |
| James S Kuo | Director | Feb 2009 |
| Cyrille Buhrman | Director | Feb 2009 |
| Evan Myrianthopoulos | Director | Feb 2009 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.